文献速递前列腺增生与排尿功能障碍男科与性医学

保留射精穹窿与标准绿激光前列腺选择性汽化术:双盲随机试验的性功能与尿动力学评估

Ejaculatory Hood Sparing versus Standard Laser Photoselective Vaporization of the Prostate: Sexual and Urodynamic Assessment through a Double Blinded, Randomized Trial.
PubMed 文献 · J Urol · 2019-11-25

这项双盲随机试验比较了保留射精穹窿的GreenLight激光前列腺选择性汽化术与标准术式,分别纳入25例和24例患者。结果显示保留射精穹窿组顺行射精率85%显著高于标准组的31.6%(p=0.001),且性功能评分下降更少,而两组尿动力学梗阻缓解和再治疗率相当。

要点

  • 保留射精穹窿组顺行射精率85%,标准组31.6%(p=0.001)。
  • 保留射精穹窿组性功能评分无显著下降,标准组在6和12月显著下降。
  • 两组尿动力学梗阻指数下降和再治疗率无显著差异。

核心结论

  • 对知情且性活跃患者,保留射精穹窿的GreenLight前列腺选择性汽化术可行且有效,性功能相关结局优于标准术式。
  • 短期梗阻缓解客观上与标准前列腺选择性汽化术相当。

研究设计与样本

  • 双盲随机试验,标准前列腺选择性汽化术24例,保留射精穹窿汽化术25例。
  • 术后1、3、6、12月评估Ej-MSHQ和IIEF-15,随访时报告I-PSS、尿流率和残余尿,6月行标准尿动力学检查。

主要发现

  • 顺行射精率保留射精穹窿组85%,标准组31.6%(p=0.001)。
  • 标准组EJ-MSHQ评分在6和12月显著下降(各p<0.001),保留射精穹窿组无显著差异(p=0.18和0.078)。
  • 6月EJ-MSHQ中位数保留射精穹窿组28.5(范围1-33),标准组9.5(范围1-35)(p=0.005);12月分别为27(范围1-33)和9(范围0-33)(p<0.001)。
  • 1年IIEF-15平均总分两组均下降,仅标准组有统计学显著性(p=0.001)。
  • 所有尿动力学指标各随访点均显著改善且组间相当;保留射精穹窿组膀胱出口梗阻指数中位数从64(范围21-207)降至23.5(范围10-53)(p=0.005),标准组从87(范围38-186)降至19.5(范围7-51)(p=0.001)。

临床怎么用

  • 对性活跃且知情的小至中度BPH患者,可考虑保留射精穹窿的GreenLight前列腺选择性汽化术以更好保留射精功能和性功能。
  • 该术式短期梗阻缓解与标准术式相当,可作为标准汽化术的替代选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In a preliminary clinical trial we assessed the efficacy of ejaculatory hood sparing GreenLight™ Laser prostate photoselective vaporization to preserve antegrade ejaculation and urodynamic relief of obstruction compared to standard GreenLight prostate photoselective vaporization. MATERIALS AND METHODS: Standard prostate photoselective vaporization was classically performed in 24 patients. Ejaculatory hood sparing vaporization was performed with preservation of the paracollicular and supracollicular tissue proximal to the verumontanum in 25 patients. Patients were assessed at baseline, and 1, 3, 6 and 12 months postoperatively using the Ej-MSHQ (Ejaculatory Domain of Male Sexual Health Questionnaire) and the IIEF-15 (International Index of Erectile Function-15). The I-PSS (International Prostate Symptom Score), uroflowmetry and post-void residual urine volume were reported at each followup visit. A standard urodynamic study was performed at 6 months. RESULTS: Antegrade ejaculation was reported in 85% and 31.6% of patients after hood sparing and standard prostate vaporization, respectively (p=0.001). A significant reduction in the EJ-MSHQ score was reported after standard vaporization at 6 and 12 months (each p <0.001) with no significant difference after hood sparing vaporization (p=0.18 and 0.078, respectively). The median EJ-MSHQ score was 28.5 (range 1 to 33) and 27 (range 1 to 33) for hood sparing vaporization, and 9.5 (range 1 to 35) and 9 (range 0 to 33) for standard vaporization at 6 (p=0.005) and 12 months (p <0.001), respectively. Each group showed a decline in the mean total IIEF-15 score at 1 year but it was statistically significant only after standard vaporization (p=0.001). All urinary outcome measures revealed comparable significant improvement at all followups. Postoperative urodynamic assessment demonstrated a significant comparable decrease in the Bladder Outlet Obstruction Index from a median of 64 (range 21 to 207) to 23.5 (range 10 to 53) after hood sparing vaporization (p=0.005) and from 87 (range 38 to 186) to 19.5 (range 7 to 51) after standard vaporization (p=0.001). At 1 year the overall re-treatment rate was comparable in the 2 groups (p=0.26). CONCLUSIONS: In well informed, sexually interested patients ejaculatory hood sparing GreenLight prostate photoselective vaporization is feasible and effective treatment of small to moderate sized benign prostatic hyperplasia with a superior sexual function related outcome. Short-term relief of obstruction is objectively comparable to that of standard prostate photoselective vaporization.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Abolazm AE, El-Hefnawy AS, Laymon M, et al. Ejaculatory Hood Sparing versus Standard Laser Photoselective Vaporization of the Prostate: Sexual and Urodynamic Assessment through a Double Blinded, Randomized Trial. J Urol. 2019. PMID: 31763948. doi:10.1097/JU.0000000000000685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。